Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population
- PMID: 32407570
- PMCID: PMC7665987
- DOI: 10.1002/acr.24255
Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population
Abstract
Objective: Hydroxychloroquine (HCQ) has been associated with improved survival among patients with systemic lupus erythematosus (SLE) from tertiary referral centers. We aimed to determine the potential impact of HCQ use on the risk of mortality among SLE patients in the general population.
Methods: We conducted a nested case-control study within an incident SLE cohort from the entire population of British Columbia, Canada. Deceased patients were matched with up to 3 living controls by age, sex, and SLE disease duration. HCQ exposure was categorized by the time between the last HCQ prescription date covered (i.e., end of supply) and the index date (i.e., death date) as current (<30 days), recent (30-365 days), remote (>365 days), or never used. We used conditional logistic regression to assess the risk of all-cause mortality associated with current or recent HCQ exposure compared with remote HCQ users.
Results: Among 6,241 patients with incident SLE, we identified 290 deceased patients and 502 matched SLE controls. Adjusted odd ratios for all-cause mortality were 0.50 (95% confidence interval [95% CI] 0.30-0.82) for current users and 2.47 (95% CI 1.21-5.05) for recent users compared with remote users. Associations were similar in subgroups according to SLE duration (≤5 years versus >5 years).
Conclusion: Our general population data support a substantial survival benefit associated with current HCQ use. Increased mortality among patients who had discontinued HCQ recently could be due to a sick stopper effect or the loss of actual HCQ benefits.
© 2020, American College of Rheumatology.
Similar articles
-
Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.Arthritis Care Res (Hoboken). 2023 Apr;75(4):743-748. doi: 10.1002/acr.24850. Epub 2022 Dec 17. Arthritis Care Res (Hoboken). 2023. PMID: 34941008 Free PMC article.
-
Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus.Arthritis Care Res (Hoboken). 2021 Jun;73(6):828-832. doi: 10.1002/acr.24494. Arthritis Care Res (Hoboken). 2021. PMID: 33098269
-
Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.Arthritis Care Res (Hoboken). 2015 Dec;67(12):1712-21. doi: 10.1002/acr.22636. Arthritis Care Res (Hoboken). 2015. PMID: 26097166 Free PMC article.
-
Hydroxychloroquine in systemic lupus erythematosus (SLE).Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14. Expert Opin Drug Saf. 2017. PMID: 27927040 Review.
-
Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature.Semin Arthritis Rheum. 2004 Apr;33(5):336-51. doi: 10.1016/j.semarthrit.2003.09.012. Semin Arthritis Rheum. 2004. PMID: 15079764 Review.
Cited by
-
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes.JAMA Netw Open. 2024 May 1;7(5):e2410677. doi: 10.1001/jamanetworkopen.2024.10677. JAMA Netw Open. 2024. PMID: 38722628 Free PMC article.
-
Effect of hydroxychloroquine blood concentration on the efficacy and ocular toxicity of systemic lupus erythematosus.Sci Rep. 2024 Apr 1;14(1):7674. doi: 10.1038/s41598-024-58391-2. Sci Rep. 2024. PMID: 38561370 Free PMC article.
-
Hydroxychloroquine use is associated with reduced mortality risk in older adults with rheumatoid arthritis.Clin Rheumatol. 2024 Jan;43(1):87-94. doi: 10.1007/s10067-023-06714-5. Epub 2023 Jul 27. Clin Rheumatol. 2024. PMID: 37498463
-
Factors Predictive of In-Hospital Mortality in Patients with Systemic Lupus Erythematosus: A Single-Centre Retrospective Analysis.Acta Med Acad. 2023 Apr;52(1):37-46. doi: 10.5644/ama2006-124.400. Acta Med Acad. 2023. PMID: 37326396 Free PMC article.
-
Researchers in rheumatology should avoid categorization of continuous predictor variables.BMC Med Res Methodol. 2023 Apr 26;23(1):104. doi: 10.1186/s12874-023-01926-4. BMC Med Res Methodol. 2023. PMID: 37101144 Free PMC article.
References
-
- Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8(9):522–33. - PubMed
-
- Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577–83. - PubMed
-
- Shinjo SK, Bonfa E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62(3):855–62. - PubMed
-
- Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–81. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical